Gliomas, the most common primary brain tumors, exhibit significant heterogeneity in terms of molecular characteristics and clinical outcomes. The identification of biomarkers that can predict patient survival and guide treatment decisions is crucial for improving outcomes in glioma patients. The CSF3R/CD114 gene has been implicated in various cancers, but its role in gliomas remains unclear. This review aims to elucidate the role of CSF3R/CD114 gene expression in gliomas and its implications for patient survival. We summarize current literature on the expression patterns of CSF3R/CD114 in gliomas, its association with clinicopathological features and its prognostic significance. Furthermore, we discuss potential mechanisms underlying the involvement of CSF3R/CD114 in glioma progression and therapy resistance. Understanding the role of CSF3R/CD114 in gliomas may lead to the development of novel therapeutic strategies and personalized treatment approaches for glioma patients.
HTML PDFShare this article
Journal of Clinical Neurology and Neurosurgery received 2 citations as per Google Scholar report
